Insulet — Feb 20, 2025 release

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2830238 2 2025 Outlook: Revenue Guidance (in constant currency): • For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: ◦ Total Omnipod of 17% to 21% ◦ U.S. Omnipod of 16% to 20% ◦ International Omnipod of 22% to 26% ◦ Drug Delivery of (55)% to (45)% • For the quarter ending March 31, 2025, the Company expects revenue growth of 22% to 25%. Revenue growth ranges by product line are: ◦ Total Omnipod of 23% to 26% ◦ U.S. Omnipod of 21% to 24% ◦ International Omnipod of 28% to 31% ◦ Drug Delivery of (10)% to (5)% Gross Margin and Operating Margin Guidance: For the year ending December 31, 2025, the Company expects gross margin of approximately 70.5% and operating margin of approximately 16.5%. Conference Call: Insulet will host a conference call at 4:30 p.m. (Eastern Time) on February 20, 2025, to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com, “Events and Presentations,” and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diab